

Investor Relations Brief

3

2026

March



Diagnostics Division: WHX Labs Dubai 2026

Bioneer participated in WHX Labs Dubai 2026 (Feb. 10–13, Dubai), conducting global sales and marketing activities to expand its presence in the Middle East, Africa, and Central Asia.

At the show, Bioneer presented ▲IRON-qPCR™, a next-generation POC molecular diagnostic system; ▲AccuLoader™, an automated sample dispensing system with contamination prevention; ▲ExiStation™, a fully automated molecular diagnostic system; and ▲ExiCycler™ 96 V5, an ultra-fast real-time PCR instrument with dramatically reduced test time and power consumption. IRON-qPCR™ drew strong interest as a premium solution capable of analyzing up to 40 pathogens per test. Its planned respiratory and hospital-acquired infection assay lineup was also seen as well suited to local demand, generating active business discussions.

ExiStation™'s simple, premixed-kit-based testing process was especially well received in lower- and middle-income countries facing workforce shortages, as it minimizes manual steps and training requirements. During the show, Bioneer held detailed discussions with key partners from Africa, the Middle East, and Central Asia regarding product demonstrations, local evaluations, product registration, and 2026 business plans, laying the groundwork for future sales and cooperation.

Building on this momentum, Bioneer will continue expanding IRON-qPCR™'s portfolio and strengthening the ExiStation™ platform to further expand its global market presence.



Business Updates

Diagnostics Division: WHX Labs Dubai 2026



Business Updates

CosmeRNA Drives Global Brand Growth

Bioneer is accelerating its CosmeRNA strategy following the launch of the CosmeRNA Care Center, the expansion of domestic online sales, and major U.S. media coverage — laying the foundation for mid- to long-term growth through stronger product credibility, broader customer touchpoints, and a stronger global brand presence.

The New York Post recently featured Korea's growing hair loss care market, spotlighting CosmeRNA as an innovative K-beauty case and the world's first RNA-based hair loss solution. Dr. Heejin Kim, a New York hair loss specialist interviewed for the article, described CosmeRNA as easy to apply and suitable for use in clinics or at home, highlighting its scientifically designed, safe, and convenient approach to scalp care — reflecting growing global interest in Bioneer's technology and product differentiation.

The coverage has raised CosmeRNA's brand awareness across North America and other global markets, contributing to increased overseas online traffic. Since its late-2025 domestic launch, Bioneer has also been expanding sales through clinics and online platforms.

Bioneer will continue expanding its differentiated, technology-based product portfolio while more closely integrating research, clinical activities, and commercial operations, further strengthening its position in the global K-beauty market.

WELLNESS

The cutting-edge hair growth treatments of South Korea — where the president has declared balding a 'matter of survival'

By Kyra Breslin

Published Feb. 2, 2026, 7:59 a.m. ET

14 Comments



The gene-silencing approach

One of the most innovative ideas in hair loss right now is CosmeRNA, an easily applied topical treatment developed in South Korea that uses small interfering RNA technology.

It works by blocking the follicle's androgen receptor — the signal that tells hair to thin and fall out — rather than suppressing the hormone systemically.



*Source: New York Post article (<https://nypost.com/2026/02/02/health/the-cutting-edge-hair-growth-treatments-of-south-korea/>)

Business Updates

CosmeRNA Launches on Naver Smart Store

CosmeRNA has officially launched on Naver Smart Store, Korea's leading e-commerce platform, expanding its presence across major online marketplaces to strengthen its domestic distribution network.

The launch extends CosmeRNA's reach beyond its own online store, improving accessibility and convenience for consumers. CosmeRNA is a scalp and hair conditioning serum based on Bioneer's RNA platform technology and global substance patents. The product has gained international recognition, including the top hair-product award at the 2024 Cosmoprof Awards in Bologna, while related research has also been published in Scientific Reports.

First launched through its official online store last December, CosmeRNA is a weekly scalp-care product for both men and women, offering a simple and convenient approach to routine scalp care. Through Naver Smart Store and other major online marketplaces, CosmeRNA is diversifying its direct-to-consumer sales channels, improving distribution efficiency, and enhancing the customer experience. Promotional initiatives, including first-purchase discounts, a 2+1 offer, subscription benefits, and review events, are also helping attract new customers and increase brand awareness.

CosmeRNA will continue to expand its online and offline sales channels in a balanced manner, delivering differentiated value through its biotechnology while strengthening its domestic, online-focused distribution strategy.




Business Updates

CosmeRNA Care Center Opens

On February 27, Bioneer opened the CosmeRNA Care Center at its Daejeon Global Center, launching a systematic scalp-care program that connects research, clinical validation, and customer experience in one setting. The center provides personalized care based on a data-driven system and standardized protocols, while strengthening product credibility and brand expertise.

Bioneer will continue to build its research capabilities through clinical and real-world data, while developing the CosmeRNA Care Center into a standardized model for future global expansion.



Business Updates

Bioneer at 2026 Hankyung Bio Insight Forum

At the Hankyung Bio Insight Forum 2026, held at Lotte Hotel Jeju from Feb. 25–27, Bioneer presented its nucleic-acid-based business expansion strategy, focusing on its overall business structure and long-term growth potential rather than individual pipeline results.

The company highlighted the stable cash flow generated by its commercialized probiotics business, BNR Thin, operated by its subsidiary AceBiome. This cash flow reduces reliance on external funding and supports self-sustaining R&D. Bioneer emphasized that its R&D capabilities are being steadily strengthened through cash flow generated from its own businesses, rather than relying on any single event or funding source.

Bioneer also outlined its vertically integrated system spanning the full nucleic acid value chain, from large-scale oligonucleotide and siRNA production to comprehensive molecular diagnostics solutions covering reagents and equipment. The company emphasized that this infrastructure offers more than cost efficiencies, enabling RNA-based technologies to advance from research to industrial-scale applications. Bioneer identified its siRNA production and quality-control capabilities as key strengths supporting expansion into therapeutics, cosmetics, and diagnostics.



Business Updates

Bioneer at 2026 Hankyung Bio Insight Forum

The forum also highlighted the differentiation of Bioneer's SAMiRNA™ platform, which is designed to deliver RNA-based therapeutics to tissues beyond the liver without requiring LNP encapsulation. The platform uses a self-assembling nanoparticle structure designed to minimize activation of the innate immune response. Bioneer noted that the platform's commercial potential has already been demonstrated through CosmeRNA, with global sales expanding and long-term patent protection in place, highlighting the potential for RNAi technology to develop into a repeatable commercial model beyond research applications.

SRN-001 was introduced as an expansion of the SAMiRNA™ platform into therapeutic applications, initially targeting idiopathic pulmonary fibrosis (IPF) through AREG/Amphiregulin and with potential applications in CKD, MASH, obesity, and cancer. This mechanism-based, multi-indication strategy is designed to leverage the same platform and mechanism across multiple indications, reducing reliance on the outcome of any single clinical trial while expanding the platform's potential value across the pipeline.

The presentation positioned Bioneer as a company integrating production infrastructure, molecular diagnostics, RNAi technology, and commercialization capabilities rather than focusing on the development of a single drug. Its platform-based technology assets, intellectual property portfolio, and industrialization capabilities provide a foundation for continued growth, including through indication expansion and strategic partnerships.

Bioneer used the forum to emphasize its strategy of building sustainable growth by integrating production, diagnostics, RNAi technology, and commercialization capabilities, with a focus on long-term, platform-driven growth rather than short-term, event-driven valuation.

HANKYUNG 한경바이오인사이트포럼 2026 HANKYUNG BIO INSIGHT FORUM

2026. 2. 25. (Wed.) - 27. (Fri.)

롯데호텔 제주(중문)

참가신청: ~2026.1.16(금) 17:00까지